Patients were ≥18 years of age with histologically confirmed and documented CD20-positive FL...Seventeen patients (65.4%) had a complete response and 3 patients (11.5%) had a partial response, for an objective response rate of 76.9%. Overall, results from CITADEL-102 suggest that the combination of parsaclisib with obinutuzumab and bendamustine... demonstrated preliminary efficacy in patients with R/R FL who progressed following prior rituximab-containing regimens.

Pts enrolled were ≥18 years with histologically confirmed CD20-positive FL, R/R to any prior rituximab-containing regimen, ECOG PS 0–2, ≥1 measurable lesion, and ≤4 prior therapies. Pts received parsaclisib 20 mg orally once daily (QD) for 8 weeks then 20 mg once weekly (QW); bendamustine 90 mg/m2 infusion on days 1 and 2 of cycles 1–6; and obinutuzumab 1000 mg infusion on days 1, 8, and 15 of cycle 1, and day 1 of cycles 2–6...ORR (95% CI) as reported by the investigator was 76.9% (56.4–91.0), with 17 pts (65.4%) achieving CR/CMR and 3 pts (11.5%) achieving PR/PMR as the best overall response. Median DOR, PFS, and OS were not reached.

Pts ≥18 years must have had histologically confirmed CD20-positive FL, R/R to any prior rituximab-containing regimen, ECOG PS 0–2, ≥1 measurable lesion, and ≤4 prior therapies. Pts received parsaclisib 20 mg once daily (QD) for 8 weeks then 20 mg once weekly (QW); bendamustine 90 mg/m2 infusion on days 1 and 2 of cycles 1–6; and obinutuzumab 1000 mg infusion on days 1, 8, and 15...ORR (95% CI) as reported by the investigator was 76.9% (56.4–91.0), with 17 pts (65.4%) achieving CR/CMR and 3 pts (11.5%) achieving PR/PMR as the best overall response.